RIPK1 and metabolic dysfunction-associated steatotic liver disease: Although clinical applications of MLKL inhibitors remain limited, elevated systemic levels of RIPK1 and MLKL have been reported in patients with inflammatory conditions such as non-alcoholic fatty liver disease [49], highlighting their pathophysiological relevance.